Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | GRM8 | O00222 | 1/20 | 0.34 |
| ▸ | GRM6 | O15303 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31527767 | 0.85 | USP2 (0.48) | USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1 | |
| SCHEMBL300199 | 0.85 | USP2 (0.48) | USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1 | |
| SCHEMBL300200 | 0.85 | USP2 (0.48) | USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1 | |
| SCHEMBL28410409 | 0.85 | USP2 (0.48) | USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1 | |
| SCHEMBL13497176 | 0.85 | USP2 (0.48) | USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1 | |
| Ethane SCHEMBL10712982 | 0.81 | USP2 (0.45) | USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1 | |
| SCHEMBL31154516 | 0.79 | SLC22A6 (0.59) | USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1 | |
| SCHEMBL1032574 | 0.79 | SLC22A6 (0.56) | USP2SLCO1B1SMN1; SMN2SLC22A6GABRR1 | |
| SCHEMBL26138078 | 0.79 | SLC22A6 (0.56) | SMN1; SMN2SLC22A6GABRR1LMNATDP1 | |
| SCHEMBL6431831 | 0.78 | USP2 (0.58) | USP2SLCO1B1GABRR1LMNASLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| EP-1537089-A4 | COMPOUNDS COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20080021050-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-7211580-B2 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1537089-A2 | COMPOUNDS COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040142949-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004009036-A2 | COMPOUNDS COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021050-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | USP2 3898/4885SLCO1B1 4379/4885SMN1; SMN2 1777/4885 |
| US-20040142949-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | USP2 3898/4885SLCO1B1 4379/4885SMN1; SMN2 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.